PRQR - ProQR Therapeutics N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.57
+0.07 (+0.60%)
As of 2:11PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.50
Open13.10
Bid12.60 x 2200
Ask12.74 x 800
Day's Range12.55 - 13.37
52 Week Range2.90 - 24.00
Volume138,011
Avg. Volume330,350
Market Cap486.849M
Beta (3Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateFeb 26, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.25
Trade prices are not sourced from all markets
  • Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
    Zacks22 days ago

    Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids

    Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.

  • GlobeNewswire22 days ago

    ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and commercialization of RNA medicines for inherited retinal diseases (IRDs). The management team will elaborate on this strategy and present advancements across its broader clinical development pipeline during an R&D day event being held today in New York. ProQR plans to independently advance its pipeline of RNA medicines to establish a multi-product, platform company in IRD.

  • Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?
    Simply Wall St.29 days ago

    Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?

    Daniel de Boer became the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) in 2012. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...

  • GlobeNewswirelast month

    ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached agreement with  the U.S. Food and Drug Administration (FDA) on the design of a Phase 2/3 pivotal trial (“ILLUMINATE”) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. LCA is the leading genetic cause of childhood blindness. Based on data from the ongoing sepofarsen Phase 1/2 trial (PQ-110-001), the doses for the Phase 2/3 trial will be 40 μg (with an 80 μg loading dose) and 80 μg (with a 160 μg loading dose).

  • Company News For Jan 3, 2019
    Zacks2 months ago

    Company News For Jan 3, 2019

    Companies in the news are: GOOGL, TSLA, PRQR, OHI and MRT

  • GlobeNewswire2 months ago

    ProQR to Host R&D Day in New York on January 29

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks2 months ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • GlobeNewswire2 months ago

    ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need.

  • GlobeNewswire2 months ago

    ProQR Therapeutics Added to NASDAQ Biotechnology Index

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.

  • Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds?
    Insider Monkey2 months ago

    Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds?

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost a third of its value since the end of July. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 30 S&P 500 stocks […]

  • GlobeNewswire2 months ago

    ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Nature Medicine. “It was enormously gratifying to see robust improvements in visual acuity and significant augmentations in the patient’s ability to detect lights, and impressive to observe these effects within the first three months following a single injection,” said Professor Artur V. Cideciyan, Ph.D., who was one of the co-investigators at the Scheie Eye Institute of the University of Pennsylvania.

  • GlobeNewswire2 months ago

    ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it was awarded an innovation credit by the Dutch government for the clinical development and efforts to obtain marketing approval (NDA/MAA) for the QR-110 program that is being developed for patients with Leber’s congenital amaurosis 10 (LCA10), a genetic eye disease that is the leading cause of childhood blindness. Repayment of the credit is triggered only by market approval of QR-110. The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs, and is aimed at the development of promising innovations.

  • GlobeNewswire3 months ago

    ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

  • ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
    Zacks3 months ago

    ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of 46.15% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    ProQR: 3Q Earnings Snapshot

    The Leiden, Netherlands-based company said it had a loss of 21 cents per share. ProQR shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...

  • Simply Wall St.4 months ago

    Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR)

    The big shareholder groups in ProQR Therapeutics NV (NASDAQ:PRQR) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a Read More...

  • Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
    Zacks5 months ago

    Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

    Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.